APLT Investor Alert: Class Action Lawsuit Reminder for Stockholders
APLT Investor Alert: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Applied Therapeutics, Inc.
Investors who own stock in Applied Therapeutics, Inc. should take note of a recent class action lawsuit that has been filed against the company. This lawsuit alleges that Applied Therapeutics made false and misleading statements regarding the efficacy of one of its lead drug candidates, known as AT-007, in treating diabetic cardiomyopathy.
According to the lawsuit, Applied Therapeutics claimed that AT-007 was effective in treating diabetic cardiomyopathy based on interim data from a Phase 1/2 study. However, the lawsuit alleges that Applied Therapeutics failed to disclose that the study was too small to reach statistical significance and that the data was not sufficient to support the drug’s efficacy claims.
As a result of these alleged misrepresentations, Applied Therapeutics’ stock price fell significantly when the truth about the study’s limitations was revealed. Investors who suffered losses as a result of this drop in stock price may be eligible to participate in the class action lawsuit against Applied Therapeutics.
If you are a stockholder of Applied Therapeutics and would like more information about the class action lawsuit, please contact Robbins LLP. Remember, it is important to stay informed about any legal proceedings that may impact your investments.
